DAPK1、RARβ及APC在甲状腺癌中的蛋白表达及意义
|
摘要
目的：探讨DAPK1、RARβ及APC三种抑癌基因,在甲状腺癌中的表达及其意义。方法：1、本课题选择3种已被确认的与腺癌相关的抑癌基因(DAPK1、RARβ和APC)；2、采用免疫组织化学S-P法检测63例甲状腺癌、21例甲状腺腺瘤、13例桥本氏甲状腺炎、10例结节性甲状腺肿及12例正常甲状腺组织中DAPK1、RARβ及APC蛋白的表达。结果：1、DAPK1在甲状腺各种疾病组织中的蛋白表达差异有统计学意义(P<0.05),DAPK1蛋白表达的阳性率从高到低依次为正常组织(83.3%,10/12)>结节性甲状腺肿(60%,6/10)>桥本氏甲状腺炎(53.8%,7/13)>甲状腺腺瘤(47.6%,10/21)>甲状腺癌(28.6%,18/63)；2、RARβ在甲状腺各种疾病组织中的蛋白表达差异有统计学意义(p<0.05),RARβ蛋白表达的阳性率从低到高依次为桥本式甲状腺炎(23.1%,3/13)<正常组织(33.3%,4/12)<结节性甲状腺肿(40.0%,4/10)<甲状腺腺瘤(61.9%,13/21)<甲状腺癌(76.2%,48/63)；3、APC在甲状腺各种疾病组织中的蛋白表达差异无统计学意义(P>0.05)；APC的蛋白表达的阳性率为正常组织(50.0%,6/12)、结节性甲状腺肿(30%,3/10)、桥本氏甲状腺炎(46.2%,6/13)、甲状腺腺瘤(38.1%,8/21)及甲状腺癌(44.4%,28/63)；4、DAPK1和RARβ蛋白表达水平与PTC和FTC的临床分期、淋巴结转移密切相关；有淋巴结转移组的DAPK1阳性率为13.5%,明显低于无转移组(44.4%)；有淋巴结转移组的RARβ阳性率为78.3%,明显高于无转移组(44.4%)；5、DAPK1、RARP和APC的蛋白表达与年龄、性别和民族无关(P>0.05)。6、在甲状腺癌中,尚不能认为DAPK1与RARβ的蛋白表达之间有相关关系(P>0.05)；尚不能认为RARβ与APC的蛋白表达之间有相关关系(p>0.05)；DAPK1与APC的蛋白表达,在甲状腺癌中呈中度正相关(r=0.445,0.4Objective:To evaluate the expression and clinical significance of DAPK1、RARβand APC in thyroid carcinoma.Methods:1. In this study, three kinds of tumor suppressor genes and abnormal gland cancer methylation genes such as DAPK1、RARβand APC,are selected,which have already been confirmed.2. Immunohistochemical stain was used to determine the protein expression of these genes in 63 cases of thyroid cancers,21 cases of thyroid adenoma,13 cases of hashimoto's thyroiditis,10 cases of nodular goiter and 12 cases of normal thyroid tissue. Results:1. The variance of DAPK1's protein expression has statistical significance in the thyroid gland various pathological tissues (P<0.05), protein expression was followed by normal thyoid tissue (83.3%, 10/12)>nodular goiter (60%,6/10)>hashimoto's thyroiditis (53.8%,7/13)>thyroid adenoma (47.6%,10/21)>thyroid cancer (28.6%,18/63); 2. The variance of RARβ's protein expression has statistical significance in the thyroid gland various pathological tissues (P<0.05), protein expression was followed by hashimoto's thyroiditis (23.1%,3 /13)0.05),and from total not significant change tendency; 4. There are statistical significance that DAPK1 and RARβis to clinical stage and lymphnode metastasis in thyroid cancer; 5. The protein expression of DAPK1、RARβand APC are nothing to do with age, gender and ethnic (P>0.05); 6.The expression of DAPK1 in thyroid cancer was positively correlated with the expression of APC (r=0.445,0.4
引文
[1]方海飞,沈美萍,徐银峰.甲状腺乳头状癌TGF-β1、CD31表达与肿瘤转移的关系[J].南京医科大学学报(自然科学版),2007,27(5)：472475.
[2]孙洁,关海霞,王立瑶,王翠芳.甲状腺乳头状癌诊断与鉴别诊断分子标志物的研究进展[J].沈阳医学院学报,2009,11(3)：182-184.
[3]许晨,赵文川.甲状腺癌分子标记物研究进展[J].现代肿瘤医学,2006,14(3)：357-360.
[4]敖小凤,高志红.甲状腺癌流行现状研究进展[J].中国慢性病预防与控制,2008,16(2)：217-219.
[5]张玉超,申虎,雷海龙,李化忠.甲状腺癌的分子生物学研究状态综述[J].中国医药指南,2010,8(10)：40-41.
[6]夏米西努尔·伊力克,热沙来提·艾尔西丁,阿布力孜·阿布杜拉等.新疆地区199例甲状腺癌临床病理分析[J].现代肿瘤医学,2008,16(6)：937-939.
[7]夏米西努尔·伊力克,尼加提·热合木,阿布力孜·阿布杜拉等.116例维、汉甲状腺疾病临床病理分析[J].新疆医科大学学报,2009,32(6)：709-713.
[8]张健.分子肿瘤标记物在甲状腺癌诊断中的意义[J].中国实用内科杂志,2007,27(17)：1337-1338.
[9]陈新焰.甲状腺癌肿瘤分子标记物新进展[J].国外医学内分泌学分册,2005,25(5)：346-349.
[10]International Union Against Cancer (UICC):TNM Classification of malignant tumors.6th ed Sobin LH, Wittekind Ch.,eds. New York:Wiley-Liss,2002.
[11]Hundahl SA, Fleming ID, Fremgen AM, el al. A National cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S.,1985-1995[J]. Cancer, 1998,83:2638-2648.
[12]徐先发,邵姗.分化型甲状腺癌的治疗策略[J].中国耳鼻咽喉头颈外科,2008,15(6)：331-334.2006,1：7-17.
[13]康新江.DNA甲基化与肿瘤[J].内肛科技,2006,3：105.
[14]伊飞鹏,于世鹏.P13K对分化型甲状腺癌中NIS表达调节的研究进展[J].国际内科学杂志,2009,36(8)：491-494.
[15]余红梅,陈世清,朱大菊等.甲状腺肿瘤相关基因的研究进展[J].临床外科杂志,2006,14(9)：597-599.
[16]Ming Zhao Xing. Gene methylation in thyroid tumor genesis [J]. Endocrinology, 2007,148:3948-953.
[17]Lee S, Hwang KS, Lee HJ, et al. Aberrant CpG island hyper-methylation of multiple genes in colorectal neoplasia[J].Lab Invest,2004,84:884-893.
[18]Xue WC, Chan KY, Feng HC,et al. Promoter hypermethylation of multiple genes in hydatidiform mole and choriocarcinoma[J]. Mol Diagn,2004,6:326-334.
[19]唐纪全,工川,傅芳萌等DAPK1基因启动子甲基化与乳腺癌临床病例特征的关系[J].国际病理科学与临床杂志,2010,30(4)：277-281.
[20]华海蓉,金克炜,阮永华等DAPK基因启动子甲基化在云锡矿粉诱导F334大鼠中的作用[J].中国职业医学,2008,35(2)：95-97.
[21]孔祥勇,胡世莲等.胃癌中DAPK基因启动子区CpG岛高甲基化的研究[J].肿瘤,2009,29(11)：1065-1069.
[22]何晶晶,毛易捷,许刚等.前列腺癌组织中GSTP1和DAPK基因异常甲基化检测及临床意义[J].实用医学杂志,2009,25(9)：1364-1364.
[23]赵先兰,孟志英等DAPK和DNMT1在宫颈癌中的相关性研究[J].免疫学杂志,2009,25(1)：80-87.
[24]花敏慧.DAPK1、RARβ甲基化联合高危型HPV检测对宫颈癌前病变及宫颈癌筛查的研究[M].南通大学硕士研究生毕业论文汇编,2009.
[25]章建军,蔡琰.维甲酸受体功能及其在肿瘤治疗中的应用[J].中国现代应用药学,2010,27(6)：490-494.
[26]Guidoboni M,Zancai P,Cariati R.Retinoic Acid Inhibits the Proliferative Response Induced by CD40 Activation and Interleukin-4 in Mantle Cell Lymphoma[J].Cancer Res,2005,65(2):587-595.
[27]Jones PA, Martienssen R. A blueprint for a Human Epigenome Project the AACR Human Epigenome Worksho [J].Cancer Res,2005,65:11241-11246.
[28]徐娟,曲芃芃.维甲酸受体α、β在卵巢组织中的表达及与卵巢肿瘤的关系[J].天津医药,2010,38(8)：651-653.
[29]Xu XC.Tumor-suppressive activity of retinoic acid receptor-beta in cancer[J].Cancer Lett,2007,253(1):14-24.
[30]Swift ME,Wallden B,Wayner EA,et al. Truncated RAR beta isoform enhances proliferation and retinoid resistance[J].J Cell Physiol,2006,209(3):748-725.
[31]Leung WK,TO KF, Chu ES, et al. Potential diagnostic and prognostic values of detecting promoter hypernethylation in the serum of patients with gastric cancer[J].Br J Cancer,2005,92(12):2190-2194.
[32]Shaw RJ, Liloglou T, Rogers SN, et al. Promoter methylation of P16, RAR beta, E-cadherin, cyclin A1 and cytoglobin in oral cancer quantitative evaluation using pyrosequencing[J].Br J Cancer,2006,94(4):561-568.
[33]Korshunova Y, M aloney RK, et al. Massively parallelbisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA [J].Genome Res,2008,18(1):19-29.
[34]Hoque MO.DNA methylation changes in prostate cancer current developments and future clinical implementation[J].Expert Rev Mol Diagn,2009,9(3):243-257.
[35]Spurling CC, Suhi JA, Boucher N, et al. The short chain fatty acid butyrate induces promoter demethylation and reactivation of RAR beta2 in colon cancer cells[J].Nutr Cancer,2008,60(5):692-702.
[36]Takacs CM,Baird JR;Hughes EG, et al. Dual positive and negative regulation of wingless signaling by adenomatous polyposis coli.Science,2008,319:333-336.
[37]韩冲,王在军,王立东.APC与肿瘤浸袭转移的关系[M].中国科技信息,2010,14：175-176.
[38]王震凯,朱人敏等β-catenin和APC蛋白在胃癌、胃腺瘤中的表达变化及研究[M].第九届国际治疗内镜和消化疾病学术会议论文汇编,2010：262-263.
[39]李飞.APC基因与大肠癌关系研究进展[J].肿瘤学杂志,2010,16(2)：108-110.
[40]王世凤,刘倩,张尚福等.APC和c-Myc在非小细胞肺癌中的表达及意义[J].四川大学学报(医学版),2010,41(5)：822-826.
[41]白同,杨斌,娄诚等.APC和CDKN2A基因甲基化定量分析对肝细胞癌的诊断价值[J].世界华人消化杂志,2009,17(29)：3001-3007.
[42]Tanaka K, Iwamooto S, Gon G, et al. Expression of survivin and its relationship to loss of apopotosis in breast carcinomas [J]. Clin Cancer Res,2000,6(1):127.
[43]周庚寅,等主编.甲状腺病理与临床[M].北京：人民卫生出版社,2005：135.
[44]沈建军,胡世莲等RUNX3、DAPK基因甲基化及其蛋白表达与胃癌病情的研究[J].安徽医科大学学报,2010,45(5)：613-617.
[45]刘晓婉等.新疆维吾尔族妇女宫颈病变中的DAPK表达的研究[J].中国肿瘤,2010,19(3)：203-206.
[46]王振宝,潘晓琳等.抑癌基因DAPK在肿瘤中的发生、转移、复发、预后中的作用[J].生命的化学,2008,28(3)：295-298.
[47]彭再梅,山长婷等.诱导痰RASSF1A, P16, DAPK基因启动子区甲基化在肺癌诊断中的价值[J].中南大学学报(医学版),2010,35(3)：247-253.
[48]Toulouse A, LoubeauM, Morin J, et al. RARbeta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis [J]. FASEB,2000,14: 1224-1232.
[49]Elisei R, Vivaldi A, Agate L, et al.All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes[J].Clin Endocrinol M etab,2005,90(4):2403-2411.
[50]Galiatsatos P, Foulkes D.Familial adenomatous polyposis[J].Am J Gastroenterol, 2006,101(2):385.
[51]潘俊,陈凌武等.膀胱癌抑癌基因Apaf-1和APC的甲基化状况及其临床意义[J].中山大学学报(医学科学版),2010,31(3)：397-405.
[52]吴雪梅等.雷公藤内酯醇逆转Jurkat细胞apc基因甲基化及其机制的初步研究[J].中国实验血液学杂志,2010,18(4)：866-872.
[53]戴文斌.Wnt通路成员APC、β-catenin、c-myc及黏附分子E-cadherin与大肠癌的关系[J].中国肿瘤临床与康复,2007,14：73-75.
[54]肖忠盛,梁庆模等.APC的结构与功能的进展[J].现代医药卫生,2010,26(4)：535-537.
[55]黄凯.APC基因在肿瘤研究中的进展[J].实用医技杂志,2003,10(4)：404-407.
[56]Su Y,Fu C,Ishikawa S,et al.APC is essential for targeting phoshorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase[J].Mol Cell,2008,32(5):652.
[57]Aoki, K, Aoki, M, Sugai, M, Harada, N, Miyoshi, H, Tsukamoto, T, Mizoshita, T, Tatematsu, M, Seno, H, et al. Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells.Oncogene,2007,26 (24):3511-3520.
[1]许晨,赵文川.甲状腺癌分子标记物研究进展[J].现代肿瘤医学,2006,14(3)：357-360.
[2]放小凤,高志红.甲状腺癌流行现状研究进展[J].中国慢性病预防与控制,2008,16(2)：217-219.
[3]Nix P, Nicolaides A, Coatesworth AP. Thyroid cancer reviewl:Presentation and investigation of thyroid cancer [J]. Int J Clin Pract,2005,59:1459-1463.
[4]方海飞,沈美萍,徐银峰.甲状癌乳头状癌TGF-β1、CD31表达与肿瘤转移的关系[J].南京医科大学学报(自然科学版),2007,27(5)：472-475.
[5]伊飞鹏,于世鹏.P13K对分化型甲状腺癌中NIS表达调节的研究进展[J].国际内科学杂志,2009,36(8)：491-494.
[6]Cohen O, Feinstein E, Kimchi A. DAP. kinase is a Ca2+/calmed. ulin-dependent, cytoskeletal-associated protein kinase with cell death-inducing functions that depend on its catalytic activity[J]. Embo J,2000,16:998-1008.
[7]Cohen O, lnbal B, Kissil JL, etal. DAP-kinase participates in I F-alpha-and Fas-induced apoptosis and its function requires the death domain[J]. J Cell Biol,2000, 146:141-148.
[8]Raveh T, Droguett G, Horwitz MS, etal. DAP kinase activates a pI9ARF/ 053-mediated apoptotic checkpoint to suppress oncogenic transformation[J]. Natl Cell Biol,2001,3:1-7.
[9]Yamanaka M, Watanabe M, Yamada Y, etal. Altered methylation of multiple genes in carcinogenesis of the prostate [J]. Int J Cancer,2003,106:
[10]Lei M, de The H.Retinoids and retinoic acid receptor in cancer[J].EJC Supplements,2003,1(2):13-18.
[11]Axel DI, Frigge A, Dittmann J, et al. All-trans retinoic acid regulates proliferation, migration, differentiation, and extracellular matrix turnover of human arterial smooth muscle cells[J].Cardiovasc Res,2001,49(4):851-862.
[12]Elisei R, Vivaldi A, Agate L, et al.All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes[J].Clin Endocrinol M etab,2005,90(4):2403-2411.
[13]Wirtanen L, Seguin C. Cloning of cDNAs encoding retinoic acid receptors RARγ1, RARγ2, and a new splicing variant, RARγ3, from Ambystoma mexicanum and characterization of their expression duringearly development[J]. Biochim Biophys Acta,2000,1492:81-93.
[14]Toulouse A, LoubeauM, Morin J, et al. RARbeta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis [J]. FASEB,2000,14: 1224-1232.
[15]肖忠盛,梁庆模.APC的结构和功能的研究进展[J].现代医药卫生,2010,26(4)：535-537.
[16]Galiatsatos P, Foulkes D.Familial adenomatous polyposis[J].Am J Gastroenterol, 2006,101(2):385.
[17]Behrens J. The role of the Wnt signaling pathway in colorectal tumori-genesis [J]. Biochem Soc Trans,2005,33(Pt4):672.
[18]戴文斌.Wnt通路成员APC、β-catenin、c-myc及黏附分子E-cadherin与大肠癌的关系[J].中国肿瘤临床与康复,2007,14：73-75.
[19]Qian J,Sarnaik AA,Bonney TM,et al.The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus[J].Gastroenterology,2008,135(1):152.
[20]Wang Y,Azuma Y,Moore D,et al.Interaction between Tumor Suppressor Adenomatous Polyposis Coli and Topoisomerase Ⅱ:Implication for the G2/M Transition.Mol[J].Biol.Cell,2008,19:4076.
[21]刘棣,蔡建春.DNA异常甲基化在肿瘤中的作用[J].Medical Recapitulate,2006 12(10):598-600.
[22]Jones PA, Martienssen R. A blueprint for a Human Epigenome Project the AACR Human Epigenome Worksho [J].Cancer Res,2005,65:11241-11246.
[23]薛京伦,主编.表观遗传学—原理、技术与实践[M].上海科学技术出版社,2006年第一版：7-17.
[24]李波,乔振华.DNA甲基化研究及其检测方法的新进展[J].山西医科大学学报,2006,37(3)：317-319.
[25]Hoque MO, Rosenbaum E, Westra WH, et al. Quantitative assessment of promoter methylation profiles in thyroid neoplasms [J].Clin Endocrinol Metab, 2006,91(9):3278.
[26]Turekp lewa J, Jagodzinski P P. The role ofmammalian DNA methyltransferases in the regulation of gene exp ression[J]. CellMolBiol Lett,2005,10 (4):631-647.
[27]李树权,刘素香.DNA甲基化与肿瘤[J].中国城乡企业卫生,2006,113(3)：37-39.
[2]孙洁,关海霞,王立瑶,王翠芳.甲状腺乳头状癌诊断与鉴别诊断分子标志物的研究进展[J].沈阳医学院学报,2009,11(3)：182-184.
[3]许晨,赵文川.甲状腺癌分子标记物研究进展[J].现代肿瘤医学,2006,14(3)：357-360.
[4]敖小凤,高志红.甲状腺癌流行现状研究进展[J].中国慢性病预防与控制,2008,16(2)：217-219.
[5]张玉超,申虎,雷海龙,李化忠.甲状腺癌的分子生物学研究状态综述[J].中国医药指南,2010,8(10)：40-41.
[6]夏米西努尔·伊力克,热沙来提·艾尔西丁,阿布力孜·阿布杜拉等.新疆地区199例甲状腺癌临床病理分析[J].现代肿瘤医学,2008,16(6)：937-939.
[7]夏米西努尔·伊力克,尼加提·热合木,阿布力孜·阿布杜拉等.116例维、汉甲状腺疾病临床病理分析[J].新疆医科大学学报,2009,32(6)：709-713.
[8]张健.分子肿瘤标记物在甲状腺癌诊断中的意义[J].中国实用内科杂志,2007,27(17)：1337-1338.
[9]陈新焰.甲状腺癌肿瘤分子标记物新进展[J].国外医学内分泌学分册,2005,25(5)：346-349.
[10]International Union Against Cancer (UICC):TNM Classification of malignant tumors.6th ed Sobin LH, Wittekind Ch.,eds. New York:Wiley-Liss,2002.
[11]Hundahl SA, Fleming ID, Fremgen AM, el al. A National cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S.,1985-1995[J]. Cancer, 1998,83:2638-2648.
[12]徐先发,邵姗.分化型甲状腺癌的治疗策略[J].中国耳鼻咽喉头颈外科,2008,15(6)：331-334.2006,1：7-17.
[13]康新江.DNA甲基化与肿瘤[J].内肛科技,2006,3：105.
[14]伊飞鹏,于世鹏.P13K对分化型甲状腺癌中NIS表达调节的研究进展[J].国际内科学杂志,2009,36(8)：491-494.
[15]余红梅,陈世清,朱大菊等.甲状腺肿瘤相关基因的研究进展[J].临床外科杂志,2006,14(9)：597-599.
[16]Ming Zhao Xing. Gene methylation in thyroid tumor genesis [J]. Endocrinology, 2007,148:3948-953.
[17]Lee S, Hwang KS, Lee HJ, et al. Aberrant CpG island hyper-methylation of multiple genes in colorectal neoplasia[J].Lab Invest,2004,84:884-893.
[18]Xue WC, Chan KY, Feng HC,et al. Promoter hypermethylation of multiple genes in hydatidiform mole and choriocarcinoma[J]. Mol Diagn,2004,6:326-334.
[19]唐纪全,工川,傅芳萌等DAPK1基因启动子甲基化与乳腺癌临床病例特征的关系[J].国际病理科学与临床杂志,2010,30(4)：277-281.
[20]华海蓉,金克炜,阮永华等DAPK基因启动子甲基化在云锡矿粉诱导F334大鼠中的作用[J].中国职业医学,2008,35(2)：95-97.
[21]孔祥勇,胡世莲等.胃癌中DAPK基因启动子区CpG岛高甲基化的研究[J].肿瘤,2009,29(11)：1065-1069.
[22]何晶晶,毛易捷,许刚等.前列腺癌组织中GSTP1和DAPK基因异常甲基化检测及临床意义[J].实用医学杂志,2009,25(9)：1364-1364.
[23]赵先兰,孟志英等DAPK和DNMT1在宫颈癌中的相关性研究[J].免疫学杂志,2009,25(1)：80-87.
[24]花敏慧.DAPK1、RARβ甲基化联合高危型HPV检测对宫颈癌前病变及宫颈癌筛查的研究[M].南通大学硕士研究生毕业论文汇编,2009.
[25]章建军,蔡琰.维甲酸受体功能及其在肿瘤治疗中的应用[J].中国现代应用药学,2010,27(6)：490-494.
[26]Guidoboni M,Zancai P,Cariati R.Retinoic Acid Inhibits the Proliferative Response Induced by CD40 Activation and Interleukin-4 in Mantle Cell Lymphoma[J].Cancer Res,2005,65(2):587-595.
[27]Jones PA, Martienssen R. A blueprint for a Human Epigenome Project the AACR Human Epigenome Worksho [J].Cancer Res,2005,65:11241-11246.
[28]徐娟,曲芃芃.维甲酸受体α、β在卵巢组织中的表达及与卵巢肿瘤的关系[J].天津医药,2010,38(8)：651-653.
[29]Xu XC.Tumor-suppressive activity of retinoic acid receptor-beta in cancer[J].Cancer Lett,2007,253(1):14-24.
[30]Swift ME,Wallden B,Wayner EA,et al. Truncated RAR beta isoform enhances proliferation and retinoid resistance[J].J Cell Physiol,2006,209(3):748-725.
[31]Leung WK,TO KF, Chu ES, et al. Potential diagnostic and prognostic values of detecting promoter hypernethylation in the serum of patients with gastric cancer[J].Br J Cancer,2005,92(12):2190-2194.
[32]Shaw RJ, Liloglou T, Rogers SN, et al. Promoter methylation of P16, RAR beta, E-cadherin, cyclin A1 and cytoglobin in oral cancer quantitative evaluation using pyrosequencing[J].Br J Cancer,2006,94(4):561-568.
[33]Korshunova Y, M aloney RK, et al. Massively parallelbisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA [J].Genome Res,2008,18(1):19-29.
[34]Hoque MO.DNA methylation changes in prostate cancer current developments and future clinical implementation[J].Expert Rev Mol Diagn,2009,9(3):243-257.
[35]Spurling CC, Suhi JA, Boucher N, et al. The short chain fatty acid butyrate induces promoter demethylation and reactivation of RAR beta2 in colon cancer cells[J].Nutr Cancer,2008,60(5):692-702.
[36]Takacs CM,Baird JR;Hughes EG, et al. Dual positive and negative regulation of wingless signaling by adenomatous polyposis coli.Science,2008,319:333-336.
[37]韩冲,王在军,王立东.APC与肿瘤浸袭转移的关系[M].中国科技信息,2010,14：175-176.
[38]王震凯,朱人敏等β-catenin和APC蛋白在胃癌、胃腺瘤中的表达变化及研究[M].第九届国际治疗内镜和消化疾病学术会议论文汇编,2010：262-263.
[39]李飞.APC基因与大肠癌关系研究进展[J].肿瘤学杂志,2010,16(2)：108-110.
[40]王世凤,刘倩,张尚福等.APC和c-Myc在非小细胞肺癌中的表达及意义[J].四川大学学报(医学版),2010,41(5)：822-826.
[41]白同,杨斌,娄诚等.APC和CDKN2A基因甲基化定量分析对肝细胞癌的诊断价值[J].世界华人消化杂志,2009,17(29)：3001-3007.
[42]Tanaka K, Iwamooto S, Gon G, et al. Expression of survivin and its relationship to loss of apopotosis in breast carcinomas [J]. Clin Cancer Res,2000,6(1):127.
[43]周庚寅,等主编.甲状腺病理与临床[M].北京：人民卫生出版社,2005：135.
[44]沈建军,胡世莲等RUNX3、DAPK基因甲基化及其蛋白表达与胃癌病情的研究[J].安徽医科大学学报,2010,45(5)：613-617.
[45]刘晓婉等.新疆维吾尔族妇女宫颈病变中的DAPK表达的研究[J].中国肿瘤,2010,19(3)：203-206.
[46]王振宝,潘晓琳等.抑癌基因DAPK在肿瘤中的发生、转移、复发、预后中的作用[J].生命的化学,2008,28(3)：295-298.
[47]彭再梅,山长婷等.诱导痰RASSF1A, P16, DAPK基因启动子区甲基化在肺癌诊断中的价值[J].中南大学学报(医学版),2010,35(3)：247-253.
[48]Toulouse A, LoubeauM, Morin J, et al. RARbeta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis [J]. FASEB,2000,14: 1224-1232.
[49]Elisei R, Vivaldi A, Agate L, et al.All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes[J].Clin Endocrinol M etab,2005,90(4):2403-2411.
[50]Galiatsatos P, Foulkes D.Familial adenomatous polyposis[J].Am J Gastroenterol, 2006,101(2):385.
[51]潘俊,陈凌武等.膀胱癌抑癌基因Apaf-1和APC的甲基化状况及其临床意义[J].中山大学学报(医学科学版),2010,31(3)：397-405.
[52]吴雪梅等.雷公藤内酯醇逆转Jurkat细胞apc基因甲基化及其机制的初步研究[J].中国实验血液学杂志,2010,18(4)：866-872.
[53]戴文斌.Wnt通路成员APC、β-catenin、c-myc及黏附分子E-cadherin与大肠癌的关系[J].中国肿瘤临床与康复,2007,14：73-75.
[54]肖忠盛,梁庆模等.APC的结构与功能的进展[J].现代医药卫生,2010,26(4)：535-537.
[55]黄凯.APC基因在肿瘤研究中的进展[J].实用医技杂志,2003,10(4)：404-407.
[56]Su Y,Fu C,Ishikawa S,et al.APC is essential for targeting phoshorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase[J].Mol Cell,2008,32(5):652.
[57]Aoki, K, Aoki, M, Sugai, M, Harada, N, Miyoshi, H, Tsukamoto, T, Mizoshita, T, Tatematsu, M, Seno, H, et al. Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells.Oncogene,2007,26 (24):3511-3520.
[1]许晨,赵文川.甲状腺癌分子标记物研究进展[J].现代肿瘤医学,2006,14(3)：357-360.
[2]放小凤,高志红.甲状腺癌流行现状研究进展[J].中国慢性病预防与控制,2008,16(2)：217-219.
[3]Nix P, Nicolaides A, Coatesworth AP. Thyroid cancer reviewl:Presentation and investigation of thyroid cancer [J]. Int J Clin Pract,2005,59:1459-1463.
[4]方海飞,沈美萍,徐银峰.甲状癌乳头状癌TGF-β1、CD31表达与肿瘤转移的关系[J].南京医科大学学报(自然科学版),2007,27(5)：472-475.
[5]伊飞鹏,于世鹏.P13K对分化型甲状腺癌中NIS表达调节的研究进展[J].国际内科学杂志,2009,36(8)：491-494.
[6]Cohen O, Feinstein E, Kimchi A. DAP. kinase is a Ca2+/calmed. ulin-dependent, cytoskeletal-associated protein kinase with cell death-inducing functions that depend on its catalytic activity[J]. Embo J,2000,16:998-1008.
[7]Cohen O, lnbal B, Kissil JL, etal. DAP-kinase participates in I F-alpha-and Fas-induced apoptosis and its function requires the death domain[J]. J Cell Biol,2000, 146:141-148.
[8]Raveh T, Droguett G, Horwitz MS, etal. DAP kinase activates a pI9ARF/ 053-mediated apoptotic checkpoint to suppress oncogenic transformation[J]. Natl Cell Biol,2001,3:1-7.
[9]Yamanaka M, Watanabe M, Yamada Y, etal. Altered methylation of multiple genes in carcinogenesis of the prostate [J]. Int J Cancer,2003,106:
[10]Lei M, de The H.Retinoids and retinoic acid receptor in cancer[J].EJC Supplements,2003,1(2):13-18.
[11]Axel DI, Frigge A, Dittmann J, et al. All-trans retinoic acid regulates proliferation, migration, differentiation, and extracellular matrix turnover of human arterial smooth muscle cells[J].Cardiovasc Res,2001,49(4):851-862.
[12]Elisei R, Vivaldi A, Agate L, et al.All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes[J].Clin Endocrinol M etab,2005,90(4):2403-2411.
[13]Wirtanen L, Seguin C. Cloning of cDNAs encoding retinoic acid receptors RARγ1, RARγ2, and a new splicing variant, RARγ3, from Ambystoma mexicanum and characterization of their expression duringearly development[J]. Biochim Biophys Acta,2000,1492:81-93.
[14]Toulouse A, LoubeauM, Morin J, et al. RARbeta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis [J]. FASEB,2000,14: 1224-1232.
[15]肖忠盛,梁庆模.APC的结构和功能的研究进展[J].现代医药卫生,2010,26(4)：535-537.
[16]Galiatsatos P, Foulkes D.Familial adenomatous polyposis[J].Am J Gastroenterol, 2006,101(2):385.
[17]Behrens J. The role of the Wnt signaling pathway in colorectal tumori-genesis [J]. Biochem Soc Trans,2005,33(Pt4):672.
[18]戴文斌.Wnt通路成员APC、β-catenin、c-myc及黏附分子E-cadherin与大肠癌的关系[J].中国肿瘤临床与康复,2007,14：73-75.
[19]Qian J,Sarnaik AA,Bonney TM,et al.The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus[J].Gastroenterology,2008,135(1):152.
[20]Wang Y,Azuma Y,Moore D,et al.Interaction between Tumor Suppressor Adenomatous Polyposis Coli and Topoisomerase Ⅱ:Implication for the G2/M Transition.Mol[J].Biol.Cell,2008,19:4076.
[21]刘棣,蔡建春.DNA异常甲基化在肿瘤中的作用[J].Medical Recapitulate,2006 12(10):598-600.
[22]Jones PA, Martienssen R. A blueprint for a Human Epigenome Project the AACR Human Epigenome Worksho [J].Cancer Res,2005,65:11241-11246.
[23]薛京伦,主编.表观遗传学—原理、技术与实践[M].上海科学技术出版社,2006年第一版：7-17.
[24]李波,乔振华.DNA甲基化研究及其检测方法的新进展[J].山西医科大学学报,2006,37(3)：317-319.
[25]Hoque MO, Rosenbaum E, Westra WH, et al. Quantitative assessment of promoter methylation profiles in thyroid neoplasms [J].Clin Endocrinol Metab, 2006,91(9):3278.
[26]Turekp lewa J, Jagodzinski P P. The role ofmammalian DNA methyltransferases in the regulation of gene exp ression[J]. CellMolBiol Lett,2005,10 (4):631-647.
[27]李树权,刘素香.DNA甲基化与肿瘤[J].中国城乡企业卫生,2006,113(3)：37-39.